137 related articles for article (PubMed ID: 23094511)
1. Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Hirata K
Osaka City Med J; 2012 Jun; 58(1):25-34. PubMed ID: 23094511
[TBL] [Abstract][Full Text] [Related]
2. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Matsuura K; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Nakai T; Hirata K
BMC Cancer; 2012 Dec; 12():568. PubMed ID: 23207012
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Takimoto T; Kijima T; Otani Y; Nonen S; Namba Y; Mori M; Yokota S; Minami S; Komuta K; Uchida J; Imamura F; Furukawa M; Tsuruta N; Fujio Y; Azuma J; Tachibana I; Kumanogoh A
Clin Lung Cancer; 2013 Sep; 14(5):502-7. PubMed ID: 23664723
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
5. Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Togashi Y; Masago K; Fujita S; Hatachi Y; Fukuhara A; Nagai H; Sakamori Y; Kim YH; Mio T; Mishima M
Lung Cancer; 2011 Oct; 74(1):98-102. PubMed ID: 21377230
[TBL] [Abstract][Full Text] [Related]
6. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
[TBL] [Abstract][Full Text] [Related]
7. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K
Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743
[TBL] [Abstract][Full Text] [Related]
8. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
9. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
[TBL] [Abstract][Full Text] [Related]
11. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Grossi F; Rijavec E; Dal Bello MG; Defferrari C; Brianti A; Barletta G; Genova C; Murolo C; Cosso M; Fontanini G; Boldrini L; Truini M; Pronzato P
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1407-12. PubMed ID: 22349923
[TBL] [Abstract][Full Text] [Related]
12. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.
Shao YY; Shau WY; Lin ZZ; Chen HM; Kuo R; Yang JC; Lai MS
Eur J Cancer; 2013 Jan; 49(1):106-14. PubMed ID: 22897841
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Hata A; Katakami N; Yoshioka H; Fujita S; Kunimasa K; Nanjo S; Otsuka K; Kaji R; Tomii K; Iwasaku M; Nishiyama A; Hayashi H; Morita S; Ishida T
Lung Cancer; 2011 Nov; 74(2):268-73. PubMed ID: 21529987
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib: new drug. Non small-cell lung cancer: like gefitinib, no established advantage.
Prescrire Int; 2006 Jun; 15(83):86-9. PubMed ID: 16764093
[TBL] [Abstract][Full Text] [Related]
16. Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R; Moran T; Queralt C; Porta R; Cardenal F; Camps C; Majem M; Lopez-Vivanco G; Isla D; Provencio M; Insa A; Massuti B; Gonzalez-Larriba JL; Paz-Ares L; Bover I; Garcia-Campelo R; Moreno MA; Catot S; Rolfo C; Reguart N; Palmero R; Sánchez JM; Bastus R; Mayo C; Bertran-Alamillo J; Molina MA; Sanchez JJ; Taron M;
N Engl J Med; 2009 Sep; 361(10):958-67. PubMed ID: 19692684
[TBL] [Abstract][Full Text] [Related]
17. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib in advanced non-small-cell lung cancer after gefitinib failure.
Zhou ZT; Xu XH; Wei Q; Lu MQ; Wang J; Wen CH
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1123-7. PubMed ID: 19322567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
